# Dialysis Initiation: Timing, Modality Selection & IDEAL Trial

## Definition of ESRD & When RRT is Needed

**ESRD = End-Stage Renal Disease:** - GFR \<15 mL/min/1.73m² (CKD Stage 5) - OR persistent symptoms of uremia despite maximal conservative management - OR acute need for RRT (hyperkalemia, pulmonary edema, severe acidosis, uremia)

Key Point

**RRT does NOT have to start immediately at GFR \<15.** Conservative management is an option for selected patients. Timing depends on symptoms, residual function, and patient preference.

------------------------------------------------------------------------

## The IDEAL Trial: Symptom-Driven vs Early Start

### **IDEAL Trial Design (2010) — UK Study**

**Question:** Does earlier dialysis initiation (eGFR 10–14) improve outcomes vs symptom-driven start (eGFR \<7)?

**Groups:** - **Early-start:** Planned RRT at eGFR 10–14 - **Symptom-driven:** RRT only when uremic symptoms appeared (median eGFR 6–7)

### **Key Findings**

| Outcome | Early Start | Symptom-Driven | Result |
|----|----|----|----|
| **Mortality** | 37% at 2 years | 37% at 2 years | **No difference** |
| **Hospitalization** | Same | Same | **No difference** |
| **Quality of life** | Same | Same | **No difference** |
| **Vascular access complications** | Higher | Lower | Better with late start |
| **Infection risk** | Similar | Similar | Similar |

Clinical Pearl

**IDEAL Trial conclusion:** Later, symptom-driven initiation is **not inferior** to early start. Avoids unnecessary early dialysis, reduces vascular access complications, preserves residual renal function longer.

### **Clinical Impact**

- Modern practice favors **later, symptom-driven initiation** (eGFR 5–10)
- Emphasis on shared decision-making with patient
- Conservative management an acceptable option for selected patients

------------------------------------------------------------------------

## Timing of Dialysis Initiation: Clinical Indicators

### **Absolute Indications (Start RRT Immediately)**

| Indication | Mechanism | Management |
|----|----|----|
| **Refractory hyperkalemia** (K \>6.5 mmol/L despite binders + diuretics) | Life-threatening arrhythmia risk | Acute HD or CRRT |
| **Pulmonary edema** (fluid overload unresponsive to diuretics) | Cardiogenic shock risk | Urgent HD (fluid removal) |
| **Severe metabolic acidosis** (pH \<7.15, refractory) | Impaired cardiac contractility | Emergent CRRT or HD |
| **Uremic pericarditis** (chest pain, friction rub, effusion) | Risk of tamponade | Urgent HD; may avoid surgery |
| **Acute poisoning** (phenobarbital, isoniazid, lithium, aspirin) | Toxin removal | CRRT or high-flux HD |

------------------------------------------------------------------------

### **Elective Indications (Can Defer if Conservative Management Selected)**

**Uremic symptoms (at eGFR 5–10):** - **Anorexia, nausea, vomiting** (reduced appetite; GI irritation from uremia) - **Fatigue, weakness** (anemia, uremia, electrolyte imbalance) - **Cognitive dysfunction** (confusion, memory, concentration decline) - **Pruritus** (itching from uremia; may be severe) - **Hypertension** uncontrolled despite 3+ antihypertensives - **Pericardial friction rub** (asymptomatic pericarditis; risk of progression)

**Biochemical parameters (less important than symptoms):** - K \>6.0 mmol/L (if symptoms or diet very restricted) - PO4 \>8 mg/dL (if refractory despite binders + diet) - PTH \>500 pg/mL (secondary HPT; may need RRT for better PTH control) - Urea \>150 mg/dL (marker of uremia; not used as sole indicator in IDEAL trial)

Clinical Warning

**Don’t start RRT based on lab value alone** — symptoms matter more. Many patients tolerate labs that “should” trigger RRT start.

------------------------------------------------------------------------

## Pre-Dialysis Planning: Vascular Access Creation

### **Timing of Access Creation**

**Fistula maturation time:** 8–12 weeks minimum (can take up to 6 months) - **Create fistula when eGFR 15–20** (3–5 years before anticipated RRT) - Start referral to vascular surgery at eGFR 25–30

**Graft maturation time:** 2–4 weeks

**Catheter:** Immediately available (tunneled central line), but temporary if possible

Clinical Pearl

**Golden rule:** Never delay nephrology referral for fear of “early” access. Fistula failures/maturation delays common — better to create early and have it ready than scramble for emergency access.

### **Types of Vascular Access**

| Type | Maturation | Longevity | Infection Risk | Flow |
|----|----|----|----|----|
| **Fistula** (AVF) | 8–12 weeks | 15–20 years | Lowest | Best (300–400 mL/min) |
| **Graft** (AVG) | 2–4 weeks | 3–5 years | Moderate | Good (250–350 mL/min) |
| **Tunneled catheter** (CVL) | Immediate | 1–2 years | Highest | Fair (200–250 mL/min) |

**Hierarchy:** Fistula \> Graft \> Catheter (avoid catheters if possible; ↑ infection, ↓ patency)

------------------------------------------------------------------------

## Modality Choice: HD vs PD vs Conservative

### **Hemodialysis (HD)**

**Mechanism:** Blood circulates outside body; semipermeable membrane removes uremic wastes + fluid

**Schedule:** - **In-center HD:** 3×/week, 4–5 hours per session - **Nocturnal HD:** 3–5×/week, 6–8 hours per session (better clearance) - **Home HD:** More flexible scheduling; better outcomes in some studies

**Advantages:** - Excellent clearance of large molecules - Rapid volume removal (good for hypervolemia, pulmonary edema) - Acute toxin removal (drug overdose, poisoning) - Works at any residual GFR

**Disadvantages:** - Vascular access complications common (stenosis, thrombosis) - Infection risk (line-related bacteremia, sepsis) - Intradialytic hypotension (especially elderly, diabetics) - Dialysis disequilibrium (rapid electrolyte shifts → cerebral edema; rare now) - Cost ≈ \$50,000/year

------------------------------------------------------------------------

### **Peritoneal Dialysis (PD)**

**Mechanism:** Peritoneal membrane (lining abdominal cavity) serves as dialyzer; dextrose-based solution creates osmotic gradient

**Schedule:** - **CAPD** (continuous ambulatory): 4–5 exchanges/day, patient-controlled - **APD** (automated peritoneal dialysis): Machine overnight, 8–10 exchanges, 8–10 hours

**Advantages:** - **Residual renal function preserved longer** (gentler ultrafiltration) - More gradual solute removal → better BP stability - Flexibility (patient-controlled schedule; can travel) - Better quality of life metrics - Home-based (no center dependency) - Lower infection risk than HD (no central line) - Easier initial training; less equipment needed

**Disadvantages:** - **Peritonitis risk** (bacterial contamination during exchanges; 0.4 episodes/patient-year) - Requires adequate peritoneal surface (obesity, adhesions, hernia contraindications) - Technique failure (peritoneal scarring, low transporter, inadequate clearance) → switch to HD - Protein loss in dialysate (1–2 g/day; malnutrition risk) - Abdominal wall hernias common (40% at 5 years) - Self-care burden higher (patient must perform exchanges)

Clinical Pearl

**When to choose PD:** Young, motivated patient; good residual function; wants flexibility; prefers home-based; fistula not feasible or failed.

------------------------------------------------------------------------

### **Conservative (Non-dialytic) Management**

**Patient selection:** - Age \>75 with comorbidities (frailty, dementia, cancer) - Declining function expected in \<1–2 years regardless - Patient preference (quality of life over quantity) - Adequate social support for symptom management

**Strategy:** 1. **Optimize medical management:** ACE-I, SGLT2i, diuretics, phosphate binders, BP control 2. **Symptom palliation:** Antiemetics, appetite stimulants, pruritus management, anemia correction 3. **Gradual dietary modification:** Progressive K, PO4, fluid restriction 4. **Palliative care consultation** when appropriate

**Outcomes:** - Median survival: 6–24 months (patient-dependent) - Better symptom control may exceed HD quality of life in selected cases - No vascular access complications, fewer hospitalizations - Natural death timeline may be preferred by patient

Clinical Warning

**Conservative management is NOT “doing nothing.”** Requires active medical management, frequent monitoring, and excellent symptom control. Not appropriate if patient wants maximum lifespan.

------------------------------------------------------------------------

## Shared Decision-Making Framework

### **Discuss at eGFR 20–25**

**Elements of informed choice:** 1. **Risks & benefits of RRT:** Timing, access complications, infection, lifestyle changes 2. **Modality comparison:** HD vs PD pros/cons tailored to patient 3. **Conservative option:** Realistic expectation of survival, quality of life 4. **Residual function:** Preserved longer with PD/conservative; lost faster with HD 5. **Transplant possibility:** If eligible, can undergo RRT while waiting 6. **Work/lifestyle impact:** HD center schedule vs PD flexibility 7. **Caregiver burden:** Family involvement in choice

### **Red Flags for Earlier Intervention Consideration**

- Diabetes + declining function (→ recommend earlier access; more complications)
- Congestive heart failure (→ HD better for fluid removal)
- Obesity (→ HD preferred; PD contraindicated if BMI \>40)
- Poor adherence anticipated (→ HD center-based better supervised)

------------------------------------------------------------------------

## Pre-RRT Labs & Optimization

### **Labs to Order (eGFR 20–25)**

- BMP: Cr, K, PO4, Ca, HCO3
- CBC: Hgb (start ESA if \<10 g/dL)
- PTH, 25-OH vitamin D
- Lipid panel (statin if not already on)
- Hepatitis panel, HIV (dialysis access safety)
- Blood cultures if any fever (exclude infection before vascular access)

### **Vaccinations Before RRT**

- Hepatitis B (if non-immune; response better at higher GFR)
- Influenza (annual)
- Pneumococcal (PCV20 × 1, or PCV15 + PPSV23)
- COVID-19 (additional doses recommended)

------------------------------------------------------------------------

## Residual Renal Function (RRF) Preservation

Key Point

**Preserving residual function is critical:** Each 1 mL/min RRF adds ~25% to urine output + solute clearance. Can mean difference between 3× vs 2×/week HD, or continued PD adequacy.

**Strategies:** 1. **Avoid nephrotoxins:** NSAIDs, ACE-I withdrawal (continue even in advanced CKD) 2. **Strict BP control:** Protects remaining nephrons 3. **Avoid contrast, surgery if possible** 4. **Optimize volume status:** Avoid both over- and under-hydration 5. **Consider late start RRT:** Preserves RRF longer than early start (IDEAL trial) 6. **PD better than HD** for RRF preservation (gentler ultrafiltration)

------------------------------------------------------------------------

## Related Resources

- Comprehensive RRT Initiation Review
- PD Physiology & Adequacy
- CRRT for Acute Kidney Injury
- CKD Staging & Referral Thresholds

------------------------------------------------------------------------

## Self-Test Questions

1.  **68M, DM, eGFR 16, K 6.1, urine output 800 mL/day, no uremic symptoms yet**
    - IDEAL trial would suggest: Wait for symptoms (symptom-driven initiation)
    - But: Create fistula now (takes 8–12 weeks to mature)
    - Shared decision-making: Discuss HD vs PD vs conservative; continue optimization
2.  **52F, eGFR 6, anorexia, nausea, pruritus, K 5.9**
    - Clear indication for RRT start: Uremic symptoms
    - Access: If fistula mature, start HD; if not ready, tunneled catheter
    - Consider PD if patient prefers flexibility + has good peritoneal function
3.  **82M with dementia, multiple comorbidities, eGFR 12, family wants “quality time”**
    - Conservative management appropriate: Palliation, symptom control
    - NOT candidate for aggressive RRT (poor predicted survival, high morbidity)
    - Palliative care + family meetings

------------------------------------------------------------------------

*Version 1.0 \| PA/Medical student level \| Evidence-based 2026-02-28*

**References:** [IDEAL trial: Early versus late initiation of dialysis (2010)](https://pubmed.ncbi.nlm.nih.gov/20581422/); [KDIGO 2024 CKD guideline](https://pubmed.ncbi.nlm.nih.gov/38490803/); [ISPD practice recommendations: high-quality goal-directed peritoneal dialysis (2020)](https://pubmed.ncbi.nlm.nih.gov/32063219/).


---

[Website version](https://urinenephrology.org/student-resources/dialysis/dialysis-initiation-student-handout.html) · Markdown synchronized October 3, 2026.